Stocks Market
Moroccan Pharma Sothema Notifies Acquisition of Eli Lilly's Cialis Assets to Competition Council
Sothema, the Moroccan pharmaceutical company, has formally notified the Competition Council of its planned acquisition of certain pharmaceutical assets from the American giant Eli Lilly and Company. The deal specifically targets the brand and products related to CIALIS, a well-known medication used for the treatment of erectile dysfunction. This strategic move by Sothema is currently under review by the regulatory body. The Competition Council has initiated a public consultation period, allowing interested third parties until December 15, 2025, to submit any observations regarding the proposed transaction. This notification is a standard regulatory step, and the Council's final assessment of the acquisition's compliance with competition rules is still pending.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
Rabat, Morocco - Société Thérapeutique Marocaine SA (Sothema), a prominent Moroccan pharmaceutical company, has officially informed the Competition Council of its intention to acquire significant pharmaceutical assets from the American drug manufacturer, Eli Lilly and Company.
The proposed transaction specifically involves the acquisition of the brand and associated products for CIALIS, a widely recognized medication primarily used in the treatment of erectile dysfunction. This move signifies a strategic expansion for Sothema within the pharmaceutical market.
Regulatory Review Underway
The Competition Council announced on December 4, 2025, that it has received the notification of this concentration operation. As per regulatory requirements, the Council has opened a 10-day period for interested third parties to submit any observations concerning the acquisition. The deadline for these submissions is set for December 15, 2025.
Eli Lilly and Company, headquartered in Indianapolis, United States, is a global pharmaceutical leader engaged in the research, development, and production of a broad range of pharmaceutical products.
It is important to note that the publication of this notice does not prejudge the Council's final assessment regarding the transaction's compliance with competition rules. The regulatory body will conduct its due diligence before issuing a definitive decision.